FOXO CEO year-end review: revenue >$15M expected, Myrtle occupancy 93%, debt reduced

FOXO TECHNOLOGIES INC.

Myrtle Recovery Centers avg daily census 28 (93% occupancy) vs 7.4 (25%) in 2024; projected 550 admissions vs 195.
Net revenues approx $12M for 9 months ended Sep 30, 2025; expects >$15M for full year 2025.
Equity increased from $5.3M (Dec 2024) to $20.2M (Sep 2025); debt reduced from $10.2M to $7.1M.
Acquired Vector BioSource; expects ~$1M net revenues in 2025; formed FOXO Acquisition Corp for future deals.
Common stock lost NYSE American listing in Q3 2025 due to share price; evaluating uplisting options for 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.